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Renal biopsy is the gold standard for providing diagnostic information 
after renal transplantation.[1,2] The most common clinical indications 
for biopsy in the first month or early post-transplant period, is 
early graft dysfunction (EGD), which may present as delayed graft 
function (DGF) or acute graft dysfunction, where a period of initial 
graft function is followed by acute deterioration.[2] Prompt therapy 
of the cause of EGD, especially when due to acute rejection (AR), 
may not only preserve graft function, but also improve long-term 
outcome.[3-5] The most common causes of EGD within the first month 
or early postoperative period are acute tubular necrosis (ATN), acute 
cellular rejection (ACR), acute antibody-mediated rejection (ABMR) 
and acute calcineurin-inhibitor (CNI) toxicity.[1,2,5] Although one can 
test for CNI levels, clinically differentiating between ATN and AR is 
very challenging; therefore, allograft biopsy is key to distinguishing 
between the two. 
Although it is considered as a valuable diagnostic tool, renal 
allograft biopsy is not without risk of major complications, including 
the need for interventional radiology procedures, operative 
exploration and graft loss.[6] Most authors have advocated a low 
threshold for early post-transplant biopsy in the setting of EGD, 
citing its relative safety and high rate of diagnosis of pathology that 
requires a change in management.[7,8] Recent studies have suggested 
that, with modern induction immunosuppression regimens, early AR 
is uncommon and routine biopsy for EGD may be unnecessary, with 
the risks outweighing the potential benefit.[9,10]
Due to the high costs associated with transplantation and follow-
up care, Africa remains underdeveloped in terms of transplantation 
services.[11] A resource-constrained environment introduces a 
number of unique variables that may predispose the renal allograft 
to a higher risk of ATN and AR, both of which may present similarly 
as EGD. Biopsies showing AR, infection or a drug reaction, lead to 
a specific change in the management of the recipient, whereas grafts 
with ATN require continuation of supportive management only. Our 
unit has historically maintained a low threshold for early graft biopsy. 
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Background. The most common clinical indication for renal biopsy in the early post-transplant period is early graft dysfunction (EGD), 
which may present either as delayed graft function (DGF) or acute graft dysfunction. Even though it is a valuable diagnostic tool, renal 
allograft biopsy is not without risk of major complications. Recent studies have suggested that, with modern immunosuppressive induction 
regimens and more accurate ways to determine high immunological risk transplants, early acute rejection (AR) is uncommon and routine 
biopsy for EGD does not result in a change in management.
Objectives. To describe the histological findings and complications of renal allograft biopsies for EGD in our setting, and to determine 
whether our current threshold for biopsy is appropriate.
Methods. This study was a retrospective audit that included all patients who underwent renal allograft biopsy within the first 30 days of 
transplantation at Groote Schuur Hospital, Cape Town, South Africa, from 1 June 2010 to 30 June 2018. The indication for biopsy was any 
patient who showed significant EGD, characterised by acute graft dysfunction or DGF with dialysis dependence.
Results. During the study period, 330 patients underwent renal transplantation, of whom 105 (32%) had an early biopsy and were included 
in the study. The median age of recipients was 39 (range 17 - 62) years, with 65% males and 35% females. The majority of donors were 
deceased donations after brain death (70%), with an overall median cold ischaemic time of 9 hours (interquartile range (IQR) 4 - 16). The 
average number of human leukocyte antigen mismatches was 5 (IQR 4 - 7). A donor-specific antibody was recorded for 18% of recipients 
and a panel-reactive antibody score of >30% was recorded for 21%. The median duration after transplant for biopsy was 8 (IQR 6 - 10) days. 
During the first month of EGD, AR was diagnosed in 42% of patients who underwent biopsies. In 21% of these patients, there was acute 
cellular rejection, in 16% antibody-mediated rejection, and in 5% both of these. Acute tubular necrosis was the primary finding in 32%, 
with acute interstitial nephritis in 8%, and acute calcineurin toxicity in 4% of cases. A significant biopsy-related complication was recorded 
in 3 patients: 1 small-bowel perforation repaired via laparotomy, and 2 vascular injuries successfully embolised by interventional radiology.
Conclusions. Considering the relative safety and high rate of detection of AR, a liberal approach to renal biopsy for EGD remains justifiable 
in our setting.
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The aim of this study was to describe the histological findings and 
complications of renal allograft biopsies for EGD in our setting, 
and to determine whether our current threshold for biopsy is 
appropriate.
Methods
This study was a retrospective audit that included all patients 
who underwent renal allograft biopsy within the first 30 days of 
transplantation at Groote Schuur Hospital, Cape Town, South 
Africa, during the study period of 1 June 2010 - 30 June 2018. The 
indication for biopsy was any patient who presented with significant 
EGD, characterised by acute graft dysfunction or DGF, with dialysis 
dependence by day 5. Unexplained haematuria and proteinuria were 
also considered indications for biopsy. Implantation biopsies (T0), as 
well as HIV-positive to positive transplant biopsies, were excluded, as 
the latter will be reported in a separate study. Where a patient had 
>1 biopsy, the first biopsy with a significant finding was recorded.
All biopsies were performed under local anaesthesia and sedation in 
the transplant unit – under ultrasound guidance. Clotting parameters 
were assessed prior to biopsy to exclude a significant coagulopathy. 
Biopsies were not performed in grafts that were ultrasonographically 
hydronephrotic. Patients were monitored in the ward during the 
night for bleeding. Biopsies were reported by a consultant pathologist 
and reviewed at a weekly multidisciplinary meeting, which included 
nephrologists familiar with transplantation care. AR was reported 
according to the latest Banff criteria.[12]
In terms of perioperative immunosuppression, all patients 
received a course of methylprednisolone post transplant: 500 mg 
on day 1, 250 mg on day 2 and 125 mg on day 3. In addition, 
20 mg oral prednisone was commenced on day 4 with the aim to 
wean by 5 mg every 2 weeks to 5 mg daily. Patients with a high 
immunological risk received antithymocyte globulin (ATG) on 
induction, and were defined by having a donor-specific antibody 
(DSA), panel-reactive antibody (PRA) >30% or a previously rejected 
transplant. High-risk patients were also commenced on tacrolimus 
and mycophenolate mofetil (MMF) on the day of transplant. Patients 
with an intermediate immunological risk received basiliximab as 
induction, and were defined by any degree of human leukocyte 
antigen (HLA) mismatch, without meeting the criteria for high 
immunological risk. Basiliximab only became available in the second 
half of 2014; therefore, before this time, intermediate-risk patients 
received only steroids for induction. Before 2017, intermediate-
risk patients were administered azathioprine and cyclosporin after 
transplantation. From 2017 onwards, all intermediate-risk patients 
were commenced on tacrolimus and MMF owing to a perceived high 
rejection rate in the unit at that time. Low-risk patients were HLA 
identical and given no induction ‒ azathioprine and cyclosporin 
being initial immunosuppressives. The desensitisation protocol for 
patients who had a confirmed DSA with associated positive-flow 
cytometry crossmatch, was 3 - 5 sessions of plasma exchange (1.5 × 
plasma volume, alternate days) and intravenous immunoglobulin 
(IVIG) 100 mg/kg administered after each session.
Statistical analysis
Statistical analysis was performed with R version 3.5.2 (https://
www.r-project.org/about.html). Numerical variables were assessed 
for normality using the Shapiro-Wilk test, and subsequently analysed 
by appropriate parametric and non-parametric tests. Categorical 
variables were analysed by Fisher’s exact and χ2 tests. Unless 
otherwise indicated, a two-tail test hypothesis was used with 0.05 as 
discriminator for rejection of the null hypothesis.
Ethical approval
Ethical approval for the study was received from the Human 
Research Ethics Committee, University of Cape Town (ref. no. HREC 
538/2018). This approval permitted a folder review of patients who 
received a transplant within the relevant time period. Informed 
consent for folder review was waived. A number of variables 
were collected, including information pertaining to the transplant 
recipient, donor, donor-recipient immunological factors and biopsy 
procedure. All patients were anonymised prior to statistical analysis.
Results
During the study period, 330 patients underwent renal transplantation, 
of whom 105 (32%) underwent an early biopsy and were included in 
the study. The median age of recipients was 39 (range 17 - 62) years, with 
65% males and 35% females. The majority were index transplants, 
with 5% being re-transplants.
Donors
The average donor age was 34 (range 14 - 67) years, with 57% males 
and 43% females. The majority of donors were deceased donations 
after brain death (70%) compared with 30% living-related donations. 
The overall median cold ischaemic time (CIT) was 9 (interquartile 
range (IQR) 4 - 16) hours. 
Immunological risk
In terms of initial CNI, 56% received cyclosporin, while 44% 
received tacrolimus. In terms of initial antimetabolite, 58% received 
azathioprine and 42% MMF. The median number of HLA mismatches 
was 5 (IQR 4 - 7). A DSA was recorded for 18% of recipients, 37% of 
whom were living-related transplants and underwent desensitisation. 
A PRA of >30% was recorded for 21%. Immunological risk was 
assessed as being high for 23%, intermediate for 72% and low for 5%. 
The most commonly used induction agent was basiliximab (27%), 
whereas 21% received ATG and 52% no specific induction agent as 
addition to the standard course of corticosteroids.
Biopsy findings
The median duration post transplant for biopsy was 8 (IQR 6 - 10) days. 
The primary findings are shown in Table 1. 
During the first month, AR was diagnosed in 42% of biopsies 
for EGD, of which 21% had ACR, 16% ABMR and 5% both. The 
second most common primary diagnosis was ATN (32%). Other 
major findings included acute interstitial nephritis (AIN) (8%) 
and acute CNI toxicity (4%). There was no statistical difference 
in the proportion of cases of AR before (37%) and after (49%) the 
introduction of basiliximab in 2014 (p=0.29).
Predicting acute rejection
Logistic regression analysis was performed to determine the effect 
of recipient, donor and immunological parameters in predicting AR. 
No factors were found to be statistically significant in predicting the 
likelihood of biopsy-proven AR in patients with EGD (Table 2).
Biopsy complications
A significant biopsy-related complication was recorded in 3 patients. 
The first had a small-bowel perforation, which was diagnosed on both 
histology and clinical evaluation the day after biopsy. The patient was 
taken for a laparotomy, where minimal peritoneal contamination was 
found and the perforation was primarily repaired, after which the 
patient had an uneventful recovery. The second patient presented 
with haematuria and a decreased haemoglobin level the day after 
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biopsy. An angiogram showed an arteriovenous fistula in the upper 
pole of the graft, which was successfully embolised. The third patient 
presented with an unexplained decrease in haemoglobin level the 
first day after biopsy. The angiogram showed an abdominal wall 
pseudoaneurysm along the biopsy tract, which was also successfully 
embolised by the interventional radiologist.
Discussion
This study describes the findings and complications of renal biopsies done 
in the first month post transplant for patients with EGD. During the study 
period, 105 of a total of 330 transplants (32%) displayed EGD in the first 
month and underwent allograft biopsy. This rate of EGD and subsequent 
biopsy are slightly higher than those in other similar units, which had a 
similar threshold for biopsy, ranging between 25% and 30%.[3,5,7]
Biopsy findings
The rate of early AR in patients who underwent biopsy in the first 
month for EGD was 42%, which is higher than the 18 - 30% found 
in similar studies.[3,5,7,8] Although just fewer than half of the patients 
in this study received tacrolimus and MMF, or a specific induction 
agent, this is much the same as regimens described in previous 
studies.[5,8] Therefore, a less aggressive immunosuppressive induction 
regimen does not account for the significantly higher incidence of AR. 
We would argue that the higher rate of AR could be due to a number 
of factors related to our developing-world setting. First, the majority of 
transplants are from deceased donors, which are inherently at greater 
risk of AR. Second, because of the ethnic diversity of our population, 
the Groote Schuur transplant unit disregards HLA matching for 
allocation, a practice which is dissimilar to that in most other centres 
worldwide. The diverse genetic exposure may lead to higher rates of 
immunogenic antigen exposure in the recipient, and thus a higher rate 
of AR than in centres with similar immunosuppressive regimens.[13]
As ATN is usually the predominant finding in patients with EGD, 
especially with DGF, it is unsurprising that this study, which found 
a high rate of AR, had a correspondingly lower rate of ATN as the 
primary finding compared with that in other studies.[2,5,7] However, 
17% of patients who had another primary finding, had ATN as a 
significant secondary finding; thus, ATN contributed to EGD in ~50% 
of cases. Numerous factors related to the local context may increase the 
risk of ATN and subsequent EGD in transplanted kidneys. First, the 
majority of transplants in our setting are from deceased donors, which 
not only have a higher risk of AR, but also a greater risk of ATN due to 
an increased CIT.[14,15] Second, the lack of a dedicated transplant theatre 
and a relatively small team of surgeons often result in an institutional 
delay from procurement to implantation, which may prolong CIT. 
Geographically, the unit also serves as the transplantation service for 
Eastern and Northern Cape provinces, which means that recipients 
may need to travel significant distances to reach the unit and be ready 
for surgery. The median CIT of transplants from deceased donors, 
which comprised 70% of cases, was 12 hours, which demonstrates 
these delays and supports the hypothesis that allografts in this setting 
may have a higher rate of EGD due to ATN. 
Complications
The major complication rate of 3% was similar to that found in other 
studies.[5,6] Although the complications were not insignificant, all 
presented within 24 hours of biopsy, and were detected and dealt with 
without major detriment to the patient or graft. This demonstrates 
the relative safety of renal biopsy for this patient group in our setting.
Threshold for biopsy: Current and future
Our unit has historically maintained a low threshold for allograft 
biopsy in the setting of EGD. This approach appears justifiable when 
Table 1. Primary findings on biopsy
Result n (%)
ATN 34 (32)
Acute rejection 44 (42)
ACR 22 (21)
ABMR 17 (16)
ACR and ABMR 5 (5)
Acute interstitial nephritis 8 (8)
Acute CNI toxicity 4 (4)
Other drug reaction 4 (4)
Acute pyelonephritis 3 (3)
Granulomatous interstitial nephritis 3 (3)
Other 6 (6)
ATN = acute tubular necrosis; ACR = acute cellular rejection; ABMR = acute antibody-
mediated rejection; CNI = calcineurin inhibitor.
Table 2. Multivariable logistic regression for factors predictive of biopsy-proven acute rejection
Parameter OR (95% CI) p-value
Recipient age 1.00 (0.94 - 1.06) 0.98
Recipient gender (male v. female) 0.92 (0.31 - 2.75) 0.90
Re-transplant 0.23 (0.01 - 2.97) 0.37
Antimetabolite (MMF v. azathioprine) 0.64 (0.05 - 5.72) 0.74
CNI (tacrolimus v. cyclosporin) 1.46 (0.13 - 22.33) 0.80
ATG/basiliximab induction 0.53 (0.11 - 2.42) 0.50
Donor age 1.01 (0.97 - 1.05) 0.71
Donor gender (male v. female) 1.08 (0.31 - 3.76) 0.92
Donor type (living v. deceased) 0.19 (0.03 - 1.04) 0.12
HLA mismatches 0.83 (0.62 - 1.09) 0.27
CIT 0.94 (0.85 - 1.04) 0.33
PRA >30% 0.68 (0.16 - 2.77) 0.65
DSA 1.68 (0.19 - 16.50) 0.70
High immunological risk 1.65 (0.15 - 19.16) 0.73
OR = odds ratio; CI = confidence interval; MMF = mycophenolate mofetil; CNI = calcineurin inhibitor; ATG = antithymocyte globulin; HLA = human leukocyte antigen;  
CIT = cold ischaemic time; PRA = panel-reactive antibody; DSA = donor-specific antibody.
694       July 2020, Vol. 110, No. 7
RESEARCH
considering the high rate of AR detected in this study, a finding 
which undeniably changes the patient’s acute post-transplantation 
management. In our setting, there is a significant shortage of 
kidneys, as well as poor access to re-transplantation, with 
patients >60 years of age not even given consideration. Therefore, 
there is little margin for error, and a delay in management of a 
rejection episode, with a consequent poorer long-term outcome, 
may be devastating to the patient. 
When compared with studies that argue against a liberal biopsy 
approach, our unit has employed a less aggressive approach to 
immunosuppressive induction. In the study by Ortiz et al.,[10] all 
patients received ATG, and in the study by Hatoum et al.,[9] every 
patient received either ATG or basiliximab. In this study, only 48% of 
patients received either ATG or basiliximab. The majority of patients 
who were not administered ATG or basiliximab, received a transplant 
before mid-2014, when basiliximab was not available for intermediate-
risk patients. From 2014 onwards, all but 2 patients received either 
ATG or basiliximab. Despite this change in induction protocol, the 
rate of AR after the introduction of basiliximab remained unchanged, 
which suggests that a less-aggressive induction regimen is not the only 
cause of the high AR rate in this setting, as discussed above.
Since 2017, both tacrolimus and MMF have become more freely 
available and are therefore readily used for immunosuppressive 
induction in our unit. Furthermore, since July 2018, we have started 
performing a complement-dependent cytotoxicity (CDC) B-cell 
crossmatch in addition to the standard T-cell crossmatch. We have 
also introduced rituximab for the prevention of ABMR in living-
donor recipients with a DSA. Despite a low threshold for biopsy 
in our setting remaining appropriate, this may not be the case in 
future. Therefore, further monitoring and reassessment of our biopsy 
findings in the clinical context of EGD are indicated.
Study limitations
As a retrospective study, our research has several weaknesses. The 
first is giving a single or primary diagnosis to a biopsy result, where 
the pathologist may have reported several significant findings. 
Where this occurred, the original biopsy report and patient records 
were reviewed by a consultant nephrologist familiar with renal 
transplantation histology, and the primary diagnosis decided as 
best possible. The second is the inclusion of a heterogeneous 
group of patients, which was done to increase the generalisability 
of the findings to all patients under the routine daily care of the 
transplant team. Furthermore, transplant recipients are by nature 
a very heterogeneous group, with multiple donor, recipient and 
perioperative factors that may affect early function and risk of 
rejection. Therefore, deciding which factor(s) should be used to 
stratify subgroups or exclude patients is problematic. In this study, 
no preoperative factors, including donor type and immunological 
risk, were found to be predictive of AR on early biopsy. However, the 
small number of patients in the study does mean a high likelihood of 
type 2 statistical error. 
Conclusions
Our unit has maintained a low threshold for renal biopsy in the setting 
of EGD and, considering the high rate of AR detected with regard to 
these early biopsies, a liberal approach remains justifiable. Transplant 
centres with similar immunosuppression protocols and demographic and 
socioeconomic settings, may use these findings to justify the cost and risk 
of biopsy in their own practice. However, advances in immunological 
screening and induction immunosuppression may demand a re-evaluation 
of the biopsy threshold for EGD in all settings, where a more conservative 
approach to biopsy may become more widely acceptable.
Declaration. None.
Acknowledgements. None.
Author contributions. DN, SP and SV collected the data; DN performed 
the statistical analysis; and DN, FCJB, ZB, TdT and EM wrote and edited 
the article. 
Funding. None.
Conflicts of interest. None.
1. Williams WW, Taheri D, Tolkoff-Rubin N, et al. Clinical role of the renal transplant biopsy. Nat Rev Nephrol 
2012;8(2):110-121. https://doi.org/10.1136/jcp.2009.067983
2. Silva DM, Garcia JP, Ribeiro AR, et al. Utility of biopsy in kidney transplants with delayed graft 
function and acute dysfunction. Transplant Proc 2007;39(2):376-377. https://doi.org/10.1016/j.
transproceed.2007.01.008 
3. Puliatti C, Rizzello A, Ilham M, et al. Efficacy of early biopsy in kidney allograft recipients 
with delayed graft function. Transplant Proc 2007;39(6):1803-1804. https://doi.org/10.1016/j.
transproceed.2007.05.015 
4. Nel D, Vogel J, Muller E, et al. Slow early graft function: A neglected entity after renal transplantation. 
Nephron Clin Pract 2012;120(4):200-204. https://doi.org/10.1159/000340032 
5. Dominguez J, Kompatzki A, Norambuena R, et al. Benefits of early biopsy on the outcome of 
kidney transplantation. Transplant Proc 2005;37(8):3361-3363. https://doi.org/10.1016/j.transproceed. 
 2005.09.030 
6. Morgan TA, Chandran S, Burger IM, et al. Complications of ultrasound‐guided renal transplant 
biopsies. Am J Transplant 2016;6(4):1298-1305. https://doi.org/10.1111/ajt.13622 
7. Gaber LW, Gaber AO, Hathaway DK, et al. Routine early biopsy of allografts with delayed function: 
Correlation of histopathology and transplant outcome. Clin Transplant 1996;10(6):629-634.
8. Jain S, Curwood V, White SA, et al. Sub‐clinical acute rejection detected using protocol 
biopsies in patients with delayed graft function. Transplant Int 2000;13(S1):52-55. https://doi.
org/10.1111/j.1432-2277.2000.tb02094.x 
9. Hatoum HH, Patel A, Venkat KK. The utility of serial allograft biopsies during delayed graft function 
in renal transplantation under current immunosuppressive regimens. ISRN Nephrol 2014;14:292305. 
https://doi.org/10.1155/2014/292305 
10. Ortiz J, Parsikia A, Mumtaz K, et al. Early allograft biopsies performed during delayed graft function 
may not be necessary under thymoglobulin induction. Exp Clin Transplant 2012;10(3):232-238. 
https://doi.org/10.6002/ect.2011.0137 
11. Muller E. Transplantation in Africa ‒ an overview. Clin Nephrol 2016;86(7):90-95. https://doi.org/ 
10.5414/ cnp86s125 
12. Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic 
criteria for chronic active T cell-mediated rejection, antibody‐mediated rejection, and prospects for 
integrative endpoints for next‐generation clinical trials. Am J Transplant 2018;18(2):293-307. https://
doi.org/10.1111/ajt.14625 
13. Trachtman H, Meisler S. Effect of race on access and outcome in renal transplantation. N Engl J Med 
1991;325(6):428-429. https://doi.org/10.1056/nejm199108083250612 
14. Pérez-Canga JL, Penagos LM, Diego RB, et al. Effect of cold ischemia time on kidney graft function 
and survival: Differences between paired kidney transplants from the same donor. Transplant Proc 
2019;51(2):321-323. https://doi.org/10.1016/j.transproceed.2018.10.012 
15. Kayler LK, Srinivas TR, Schold JD. Influence of CIT‐induced DGF on kidney transplant outcomes. 
Am J Transplant 2011;11(12):2657-2664. https://doi.org/10.1111/j.1600-6143.2011.03817.x 
Accepted 14 February 2020.
